George Yancopoulos, Regeneron president and CSO (Regeneron)

Re­gen­eron scores la­bel ex­pan­sion for cho­les­terol drug Evkeeza

Re­gen­eron’s drug for a rare dis­ease that caus­es high cho­les­terol has been ex­pand­ed to in­clude chil­dren ages 5 to 11 years old af­ter an ap­proval from the FDA.

The mAb Evkeeza, ini­tial­ly ap­proved in Feb. 2021 as an ad­junct to oth­er lipid-low­er­ing ther­a­pies in pa­tients 12 years and old­er with the rare ho­mozy­gous fa­mil­ial hy­per­c­ho­les­terolemia (HoFH). It works by block­ing the func­tion of an­giopoi­etin-like 3, a pro­tein that plays a key role in lipid me­tab­o­lism.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters